Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 32

1.

Evaluation of the American-English Quality of Life in Short Stature Youth (QoLISSY) questionnaire in the United States.

Bullinger M, Sommer R, Pleil A, Mauras N, Ross J, Newfield R, Silverman L, Rohenkohl A, Fox J, Quitmann J.

Health Qual Life Outcomes. 2015 Apr 2;13:43. doi: 10.1186/s12955-015-0236-2.

2.

Cross-cultural equivalence of the patient- and parent-reported quality of life in short stature youth (QoLISSY) questionnaire.

Bullinger M, Quitmann J, Silva N, Rohenkohl A, Chaplin JE, DeBusk K, Mimoun E, Feigerlova E, Herdman M, Sanz D, Wollmann H, Pleil A, Power M.

Horm Res Paediatr. 2014;82(1):18-30. doi: 10.1159/000358832. Epub 2014 Jun 11.

PMID:
24923908
3.
4.

Parental perception of health-related quality of life in children and adolescents with short stature: literature review and introduction of the parent-reported QoLISSY instrument.

Quitmann J, Rohenkohl A, Bullinger M, Chaplin JE, Herdman M, Sanz D, Mimoun E, Feigerlova E, DeBusk K, Power M, Wollmann H, Pleil A.

Pediatr Endocrinol Rev. 2013 Dec;11(2):147-60. Review.

PMID:
24575550
5.

Pediatric patient-reported outcome instruments for research to support medical product labeling: report of the ISPOR PRO good research practices for the assessment of children and adolescents task force.

Matza LS, Patrick DL, Riley AW, Alexander JJ, Rajmil L, Pleil AM, Bullinger M.

Value Health. 2013 Jun;16(4):461-79. doi: 10.1016/j.jval.2013.04.004.

PMID:
23796280
6.

Assessing the quality of life of health-referred children and adolescents with short stature: development and psychometric testing of the QoLISSY instrument.

Bullinger M, Quitmann J, Power M, Herdman M, Mimoun E, DeBusk K, Feigerlova E, Lunde C, Dellenmark-Blom M, Sanz D, Rohenkohl A, Pleil A, Wollmann H, Chaplin JE.

Health Qual Life Outcomes. 2013 May 7;11:76. doi: 10.1186/1477-7525-11-76.

7.

Psychometric validation of the Visual Function Questionnaire-25 in patients with diabetic macular edema.

Lloyd AJ, Loftus J, Turner M, Lai G, Pleil A.

Health Qual Life Outcomes. 2013 Jan 24;11:10. doi: 10.1186/1477-7525-11-10.

8.

Psychometric assessment of the Injection Pen Assessment Questionnaire (IPAQ): measuring ease of use and preference with injection pens for human growth hormone.

Pleil AM, Kimel M, McCormack J, Rajicic N, Hey-Hadavi J.

Health Qual Life Outcomes. 2012 Oct 9;10:126. doi: 10.1186/1477-7525-10-126.

9.

Changes in vision- and health-related quality of life in patients with diabetic macular edema treated with pegaptanib sodium or sham.

Loftus JV, Sultan MB, Pleil AM; Macugen 1013 Study Group.

Invest Ophthalmol Vis Sci. 2011 Sep 29;52(10):7498-505. doi: 10.1167/iovs.11-7613.

PMID:
21896838
10.

Patient preferences in the treatment of diabetic retinopathy.

Wirostko B, Beusterien K, Grinspan J, Ciulla T, Gonder J, Barsdorf A, Pleil A.

Patient Prefer Adherence. 2011;5:229-37. doi: 10.2147/PPA.S11972. Epub 2011 May 24.

11.

Clinical risk factors for age-related macular degeneration: a systematic review and meta-analysis.

Chakravarthy U, Wong TY, Fletcher A, Piault E, Evans C, Zlateva G, Buggage R, Pleil A, Mitchell P.

BMC Ophthalmol. 2010 Dec 13;10:31. doi: 10.1186/1471-2415-10-31. Review.

12.

Ease of use and preference for a new disposable self-injection pen compared with a reusable pen for administering recombinant human growth hormone: A multicenter, 2-month, single-arm, open-label clinical trial in patient-caregiver dyads.

Hey-Hadavi J, Pleil A, Deeb LC, Fuqua JS, Silverman LA, Reiner B, Newfield R, Rajicic N, Wajnrajch MP, Cara JF.

Clin Ther. 2010 Nov;32(12):2036-47. doi: 10.1016/j.clinthera.2010.11.007.

PMID:
21118739
13.

Patient preferences for diabetic retinopathy health States.

Szabo SM, Beusterien KM, Pleil AM, Wirostko B, Potter MJ, Tildesley H, Gonder J, Barsdorf A, Levy AR.

Invest Ophthalmol Vis Sci. 2010 Jul;51(7):3387-94. doi: 10.1167/iovs.09-4194. Epub 2010 Jan 6.

PMID:
20053977
14.

Rates of progression in diabetic retinopathy during different time periods: a systematic review and meta-analysis.

Wong TY, Mwamburi M, Klein R, Larsen M, Flynn H, Hernandez-Medina M, Ranganathan G, Wirostko B, Pleil A, Mitchell P.

Diabetes Care. 2009 Dec;32(12):2307-13. doi: 10.2337/dc09-0615.

15.

Predicting EQ-5D utility scores from the 25-item National Eye Institute Vision Function Questionnaire (NEI-VFQ 25) in patients with age-related macular degeneration.

Payakachat N, Summers KH, Pleil AM, Murawski MM, Thomas J 3rd, Jennings K, Anderson JG.

Qual Life Res. 2009 Sep;18(7):801-13. doi: 10.1007/s11136-009-9499-6. Epub 2009 Jun 19.

PMID:
19543808
16.

Joint assessment of intended and unintended effects of medications: an example using vascular endothelial growth factor inhibitors for neovascular age-related macular degeneration.

Levy AR, Szabo S, Briggs A, Pleil A, Davie A, Zlateva G, Javitt J.

J Ophthalmol. 2009;2009:540431. doi: 10.1155/2009/540431. Epub 2010 Feb 16.

17.

Photodynamic therapy with verteporfin in age-related macular degeneration: a systematic review of efficacy, safety, treatment modifications and pharmacoeconomic properties.

Cruess AF, Zlateva G, Pleil AM, Wirostko B.

Acta Ophthalmol. 2009 Mar;87(2):118-32. doi: 10.1111/j.1755-3768.2008.01218.x. Epub 2008 Jun 13. Review.

PMID:
18577193
18.

Cost-effectiveness model for neovascular age-related macular degeneration: comparing early and late treatment with pegaptanib sodium based on visual acuity.

Javitt JC, Zlateva GP, Earnshaw SR, Pleil AM, Graham CN, Brogan AJ, Shah SN, Adamis AP.

Value Health. 2008 Jul-Aug;11(4):563-74. doi: 10.1111/j.1524-4733.2007.00283.x. Epub 2007 Dec 17.

PMID:
18179676
19.

The validation of patient-rated global assessments of treatment benefit, satisfaction, and willingness to continue--the BSW.

Pleil AM, Coyne KS, Reese PR, Jumadilova Z, Rovner ES, Kelleher CJ.

Value Health. 2005 Nov-Dec;8 Suppl 1:S25-34.

PMID:
16336486
20.

How much is enough and who says so?

Kelleher CJ, Pleil AM, Reese PR, Burgess SM, Brodish PH.

BJOG. 2004 Jun;111(6):605-12.

PMID:
15198790
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk